Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 979500

Cognitive, behavioral and metabolic effects of oral galactose treatment in the transgenic Tg2576 mice


Babić Perhoč, Ana; Osmanović Barilar, Jelena; Knezović, Ana; Farkaš, Vladimir; Bagarić, Robert; Švarc, Alfred; Grünblatt, Edna; Riederer, Peter; Šalković-Petrišić, Melita
Cognitive, behavioral and metabolic effects of oral galactose treatment in the transgenic Tg2576 mice // Neuropharmacology, 148 (2018), 50-67 doi:10.1016/j.neuropharm.2018.12.018 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 979500 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Cognitive, behavioral and metabolic effects of oral galactose treatment in the transgenic Tg2576 mice

Autori
Babić Perhoč, Ana ; Osmanović Barilar, Jelena ; Knezović, Ana ; Farkaš, Vladimir ; Bagarić, Robert ; Švarc, Alfred ; Grünblatt, Edna ; Riederer, Peter ; Šalković-Petrišić, Melita

Izvornik
Neuropharmacology (0028-3908) 148 (2018); 50-67

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Alzheimer disease ; Galactose ; Metabolism ; Transgenic mice ; Positron-emission tomography ; Cognition

Sažetak
Alzheimer's disease (AD) is the most common neurodegenerative disorder associated with insulin resistance and glucose hypometabolism in the brain. Oral administration of galactose, a nutrient that provides an alternative source of energy, prevents and ameliorates early cognitive impairment in a streptozotocin- induced model (STZ-icv) of the sporadic AD (sAD). Here we explored the influence of 2- month oral galactose treatment (200 mg/kg/day) in the familial AD (fAD) by using 5- (5M) and 10- (10M) month-old transgenic Tg2576 mice mimicking the presymptomatic and the mild stage of fAD, and compared it to that observed in 7- month old STZ-icv rats mimicking mild-to- moderate sAD. Cognitive and behavioral performance was tested by Morris Water Maze, Open Field and Elevated Plus Maze tests, and metabolic status by intraperitoneal glucose tolerance test and fluorodeoxyglucose Positron- Emission Tomography scan. The level of insulin, glucagon-like peptide-1 (GLP-1) and soluble amyloid β1-42 (sAβ1-42) was measured by ELISA and the protein expression of insulin receptor (IR), glycogen synthase kinase-3β (GSK-3β), and pre-/post-synaptic markers by Western blot analysis. Although galactose normalized alterations in cerebral glucose metabolism in all Tg2576 mice (5M+2M ; 10M+2M) and STZ-icv rats, it did not improve cognitive impairment in either model. Improvement of reduced grooming behavior and normalization in reduced plasma insulin levels were seen only in 5M+2M Tg2576 mice while in 10M+2M Tg2576 mice oral galactose induced metabolic exacerbation at the level of plasma insulin, GLP-1 homeostasis and glucose intolerance, and additionally increased hippocampal sAβ1-42 level, decreased IR expression and increased GSK-3β activity. The results indicate that therapeutic potential of oral galactose seems to depend on the stage and the type/model of AD and to differ in the absence and the presence of AD-like pathology.

Izvorni jezik
Engleski



POVEZANOST RADA


Projekti:
HRZZ-IP-2014-09-4639 - TERAPIJSKI POTENCIJAL ORALNE GALAKTOZE U EKSPERIMENTALNOJ ALZHEIMEROVOJ BOLESTI (GALAD) (Melita Šalković, Petrišić) ( CroRIS)

Ustanove:
Institut "Ruđer Bošković", Zagreb,
Medicinski fakultet, Zagreb

Poveznice na cjeloviti tekst rada:

doi doi.org www.sciencedirect.com

Citiraj ovu publikaciju:

Babić Perhoč, Ana; Osmanović Barilar, Jelena; Knezović, Ana; Farkaš, Vladimir; Bagarić, Robert; Švarc, Alfred; Grünblatt, Edna; Riederer, Peter; Šalković-Petrišić, Melita
Cognitive, behavioral and metabolic effects of oral galactose treatment in the transgenic Tg2576 mice // Neuropharmacology, 148 (2018), 50-67 doi:10.1016/j.neuropharm.2018.12.018 (međunarodna recenzija, članak, znanstveni)
Babić Perhoč, A., Osmanović Barilar, J., Knezović, A., Farkaš, V., Bagarić, R., Švarc, A., Grünblatt, E., Riederer, P. & Šalković-Petrišić, M. (2018) Cognitive, behavioral and metabolic effects of oral galactose treatment in the transgenic Tg2576 mice. Neuropharmacology, 148, 50-67 doi:10.1016/j.neuropharm.2018.12.018.
@article{article, author = {Babi\'{c} Perho\v{c}, Ana and Osmanovi\'{c} Barilar, Jelena and Knezovi\'{c}, Ana and Farka\v{s}, Vladimir and Bagari\'{c}, Robert and \v{S}varc, Alfred and Gr\"{u}nblatt, Edna and Riederer, Peter and \v{S}alkovi\'{c}-Petri\v{s}i\'{c}, Melita}, year = {2018}, pages = {50-67}, DOI = {10.1016/j.neuropharm.2018.12.018}, keywords = {Alzheimer disease, Galactose, Metabolism, Transgenic mice, Positron-emission tomography, Cognition}, journal = {Neuropharmacology}, doi = {10.1016/j.neuropharm.2018.12.018}, volume = {148}, issn = {0028-3908}, title = {Cognitive, behavioral and metabolic effects of oral galactose treatment in the transgenic Tg2576 mice}, keyword = {Alzheimer disease, Galactose, Metabolism, Transgenic mice, Positron-emission tomography, Cognition} }
@article{article, author = {Babi\'{c} Perho\v{c}, Ana and Osmanovi\'{c} Barilar, Jelena and Knezovi\'{c}, Ana and Farka\v{s}, Vladimir and Bagari\'{c}, Robert and \v{S}varc, Alfred and Gr\"{u}nblatt, Edna and Riederer, Peter and \v{S}alkovi\'{c}-Petri\v{s}i\'{c}, Melita}, year = {2018}, pages = {50-67}, DOI = {10.1016/j.neuropharm.2018.12.018}, keywords = {Alzheimer disease, Galactose, Metabolism, Transgenic mice, Positron-emission tomography, Cognition}, journal = {Neuropharmacology}, doi = {10.1016/j.neuropharm.2018.12.018}, volume = {148}, issn = {0028-3908}, title = {Cognitive, behavioral and metabolic effects of oral galactose treatment in the transgenic Tg2576 mice}, keyword = {Alzheimer disease, Galactose, Metabolism, Transgenic mice, Positron-emission tomography, Cognition} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font